FIREFLY NEUROSCIENCE, INC.
NASDAQ: AIFF (Firefly Neuroscience, Inc.)
Last update: 1 hour ago2.33
-0.06 (-2.51%)
| Previous Close | 2.39 |
| Open | 2.42 |
| Volume | 52,693 |
| Avg. Volume (3M) | 208,362 |
| Market Cap | 19,812,828 |
| Price / Sales | 50.28 |
| Price / Book | 9.37 |
| 52 Weeks Range |
| Operating Margin (TTM) | -12,590.00% |
| Diluted EPS (TTM) | -0.300 |
| Quarterly Revenue Growth (YOY) | -97.80% |
| Current Ratio (MRQ) | 0.210 |
| Operating Cash Flow (TTM) | -3.65 M |
Market Trend
| Short Term | Medium Term | ||
| Industry | Software - Application (US) | Bullish | Bullish |
| Software - Application (Global) | Bullish | Bullish | |
| Stock | Firefly Neuroscience, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.63 |
|
Firefly Neuroscience Inc is an AI company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support better outcomes for people suffering from mental illnesses and cognitive disorders. |
|
| Sector | Technology |
| Industry | Software - Application |
| % Held by Insiders | 68.85% |
| % Held by Institutions | 1.76% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Waldron Private Wealth Llc | 30 Sep 2024 | 12,000 |
| Wexford Capital Lp | 30 Sep 2024 | 961 |
| Continuum Advisory, Llc | 30 Sep 2024 | 23 |
| Trueblood Wealth Management, Llc | 30 Sep 2024 | 0 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Dec 2024 | Announcement | Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman |
| 14 Nov 2024 | Announcement | Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update |
| 06 Nov 2024 | Announcement | Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event |
| 25 Oct 2024 | Announcement | Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 16 Oct 2024 | Announcement | Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology |
| 15 Oct 2024 | Announcement | Firefly Neuroscience Announces Use of Its Brain Network Analytics Platform in Phase 1 Study of SP-624, the First Potential Treatment Designed for Women with Major Depressive Disorder |
| 11 Oct 2024 | Announcement | Firefly Neuroscience to Participate in Upcoming October Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |